Abstract: The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Abstract: The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Abstract: The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.

Abstract: The present disclosure relates generally to compositions and methods for diagnosing and treating idiopathic pulmonary fibrosis (IPF). Also, methods for identifying IPF disease severity and likelihood for disease progression. An IPF patient can be identified when the CSF1 concentration or soluble CSF1R concentration in a blood sample is decreased as compared to a reference blood sample from a reference human subject not having IPF, and/or when the soluble CSF1R concentration in a bronchoalveolar lavage (BAL) fluid sample is increased as compared to a reference BAL fluid sample from the reference human subject. Once identified, the patient can be treated with, for instance, CSF1 or CSF1R inhibitors, such as antibodies. Moreover, the IPF patient soluble CSF1R level in blood or BAL samples can also be used to assess the severity of disease, and to both monitor disease progression and treatment outcomes.

Abstract: The present disclosure provides compositions and methods for intra-articular delivery of anti-CSF1R antibodies to a tissue that is impacted by a disease that is treatable with CSF1/CSF1R inhibition and/or that expresses CSF1R. It was conventional knowledge that the intra-articular dwell time of proteins in joints is typically a few hours or less. The present disclosure shows, however, that intra-articular delivery of an anti-CSF1R antibody can lead to sustained exposure and pharmacologic activity of the antibody in the joints far beyond a few hours, providing an effective means for targeted and extended delivery of the therapeutic agent.

Abstract: Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

Abstract: The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.

Abstract: Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

Abstract: The present disclosure provides compositions and methods for extended release of certain types of antibodies in vivo. It was discovered that such antibodies are able to initiate reversible gelation of hyaluronic acid (HA) by creating a depot that dissociates over time to release the antibody without any impact on its physical and chemical properties as well as its biological activity. As certain tissues and organs, such as eyes, joints and skins, contain HA, local injection of the antibodies to these tissues or organs will result in embedding of the antibody in gel formed from the HA, which becomes a repository of slow-released antibodies. In addition, slow-released formulations can be prepared with antibodies mixed with HA, optionally with other polymers.

Abstract: Provided are high concentration stable formulations of anti-CSF1R/CSF1 antibodies. An example formulation includes 105 to 250 mg/mL of the antibody, 100 mM to 200 mM of arginine glutamate or arginine HCl, 10 mM to 50 mM histidine, and 0.015 to 0.035 w/v % of polysorbate 80, at a pH of 5.4 to 5.6. Also provided are methods of using the formulations for treating diseases.

Abstract: Embodiments relate generally to gas detector connectivity devices, for example a dongle, to allow for continuous communication of real-time data between a gas detector and a central station. Dongle embodiments typically comprise an IR transceiver, a processor, a wireless interface device, a power source, and a means of attachment. Such dongle embodiments, and their related methods of operation, may allow for retrofitting of legacy gas detectors to provide wireless capabilities.

Abstract: Embodiments relate generally to systems and methods for updating the location information for a gas detector device. A gas detector device may comprise a wireless receiver operable to receive information from one or more wireless beacons. In some cases, the wireless beacons may comprise location information. When the gas detector device receives a wireless beacon, the location information stored on the gas detector device may be updated accordingly. In some cases, the subsequent readings of the gas detector device may be associated with the updated location information. In some cases, the wireless beacons may be located at critical areas within a facility, such as entrances or exits to locations.

Abstract: Embodiments relate generally to systems and methods for completing processes on a gas detector device using near-field communication between the gas detector device and an NFC tag. The NFC tag may communicate instructions or information to the gas detector device. The NFC tag may be located on or near a gas testing system, comprising gas deliver tube(s), gas tank(s), as well as other elements. In some embodiments, the gas detector device may comprise a single button to simplify interactions with the user.

Abstract: Embodiments relate generally to systems and methods for updating the location information for a gas detector device. A gas detector device may comprise a wireless receiver operable to receive information from one or more wireless beacons. In some cases, the wireless beacons may comprise location information. When the gas detector device receives a wireless beacon, the location information stored on the gas detector device may be updated accordingly. In some cases, the subsequent readings of the gas detector device may be associated with the updated location information. In some cases, the wireless beacons may be located at critical areas within a facility, such as entrances or exits to locations.

Abstract: Embodiments relate generally to gas detector connectivity devices, for example a dongle, to allow for continuous communication of real-time data between a gas detector and a central station. Dongle embodiments typically comprise an IR transceiver, a processor, a wireless interface device, a power source, and a means of attachment. Such dongle embodiments, and their related methods of operation, may allow for retrofitting of legacy gas detectors to provide wireless capabilities.

Abstract: Embodiments relate generally to systems and methods for updating the location information for a gas detector device. A gas detector device may comprise a wireless receiver operable to receive information from one or more wireless beacons. In some cases, the wireless beacons may comprise location information. When the gas detector device receives a wireless beacon, the location information stored on the gas detector device may be updated accordingly. In some cases, the subsequent readings of the gas detector device may be associated with the updated location information. In some cases, the wireless beacons may be located at critical areas within a facility, such as entrances or exits to locations.

Abstract: Embodiments relate generally to systems and methods for updating the location information for a gas detector device. A gas detector device may comprise a wireless scanner operable to receive information from one or more passive tags. In some cases, the passive tags may comprise location information. When the gas detector scans a passive tag, the location information stored on the gas detector may be updated accordingly. In some cases, the subsequent readings of the gas detector may be associated with the updated location information. In some cases, the passive tags may be located at critical areas within a facility, such as entrances or exits to locations.

Abstract: Embodiments relate generally to systems and methods for completing processes on a gas detector device using near-field communication between the gas detector device and an NFC tag. The NFC tag may communicate instructions or information to the gas detector device. The NFC tag may be located on or near a gas testing system, comprising gas deliver tube(s), gas tank(s), as well as other elements. In some embodiments, the gas detector device may comprise a single button to simplify interactions with the user.

Abstract: Embodiments relate generally to systems and methods for indicating when a gas detector is out of compliance. A Bluetooth Low Energy (BLE) enabled wireless gas-detector may allow for an advertisement packet to be transmitted from the gas detector. This advertisement packet may contain information about the gas detector to allow remote auditing from any BLE enabled remote listening device. This auditor device may be in the form of a mobile device, such as a cell phone or tablet, a fixed location auditor device, or any other BLE enabled device.

Abstract: Embodiments relate generally to systems and methods for updating the location information for a gas detector device. A gas detector device may comprise a wireless receiver operable to receive information from one or more wireless beacons. In some cases, the wireless beacons may comprise location information. When the gas detector device receives a wireless beacon, the location information stored on the gas detector device may be updated accordingly. In some cases, the subsequent readings of the gas detector device may be associated with the updated location information. In some cases, the wireless beacons may be located at critical areas within a facility, such as entrances or exits to locations.